UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

__________________

 

FORM 8-K

__________________

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) October 29, 2019

__________________

 

EYENOVIA, INC.

(Exact name of registrant as specified in its charter)

__________________

 

Delaware

(State or other jurisdiction of incorporation)

 

001-38365   47-1178401
(Commission File Number)   (IRS Employer Identification No.)

 

          295 Madison Avenue, Suite 2400, New York, New York 10017          

(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code (917) 289-1117

__________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 Par Value   EYEN   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this Chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01. Other Events.

 

On October 29, 2019, Eyenovia, Inc. (the “Company”) issued a press release announcing that it is advancing the development of its MicroLine program for the improvement in near vision in patients with presbyopia towards Phase III development. The Company also is prioritizing its MicroPine (progressive myopia) and MicroStat (mydriasis) programs while deferring development activities for its MicroProst (glaucoma and ocular hypertension) and MicroTears (red eye and itch relieve/lubrication) programs. The Company will host a conference call at 5:00 p.m. ET on October 29, 2019 to discuss its reprioritized pipeline. A copy of the press release and the slides that the Company will use in connection with the conference call are attached as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

 

Exhibit No. 

 

Description 

  99.1   Press release dated October 29, 2019.
       
  99.2   Reprioritized pipeline presentation.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  EYENOVIA, INC.
     
     
Date: October 29, 2019 By: /s/ John Gandolfo
    Name: John Gandolfo
    Title: Chief Financial Officer

 

 

 

Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Apr 2020 to May 2020 Click Here for more Eyenovia Charts.
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From May 2019 to May 2020 Click Here for more Eyenovia Charts.